



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Wednesday, December 1, 2021, 1:00pm
DMAS -- 600 East Broad Street

Agenda

1. **Call to Order and Introductions** – John Morgan, MD, Chief Clinical Innovation Officer, Chair
2. **Minutes - Approval of Minutes from the June 10, 2021 and September 9, 2021 meetings**
3. **New Drugs from September 9, 2021 DUR Meeting - Grid**
 - a) Fotivda[®] (tivozanib) *
 - b) Lumakras[™] (sotorasib) **
 - c) Myfembree[®] (relugolix, estradiol, and norethindrone acetate)
 - d) Truseltiq[™] (infigratinib)
 - e) Wegovy[™] (semaglutide)
4. **New Drugs for December 9, 2021 DUR Meeting - Grid**
 - a) Exkivity[™] (mobocertinib) **
 - b) Kerendia[®] (finerenone)
 - c) Welireg[™] (belzutifan) *
5. **Utilization Management (UM)**
 - a) Movement Disorders
 - b) HIV
6. **Class Criteria**
 - a) Hepatitis C
 - b) Oral Hypoglycemic
 - c) Oral Oncology – Lung Cancer **
 - d) Oral Oncology – Renal Cell Carcinoma *



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

7. **MRx Pipeline/DUR Quarterly Newsletter – Available on WebPortal**
8. **Topics for Discussion**
 - a) Concurrent Use of Opioids and Benzodiazepines
 - b) Concurrent Use of Opioids and Antipsychotics
 - c) Antipsychotic Medications in Children
9. **Surveillance**
 - a) Opioid Use with Risk Factors with and without Naloxone
10. **Reports**
 - a) ProDUR
 - b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
 - c) Utilization Analysis
11. **Adjournment**